Compare GoPro Inc (GPRO) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Tango Therapeutics Inc. — how do they compare? GoPro Inc trades at $1.1 (market cap $238.34M), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is far larger — about 15.7× GoPro Inc's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Tango Therapeutics Inc. for 0 Days on average.
| GPRO | TNGX | |
|---|---|---|
Market Cap | $238.34M | $3.74B |
Volume | 5,242,039 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $2.31 | $32.90 |
52-Week Low | $0.58 | $7.50 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $297.12M | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $1.18, down 0.84% on the day, following recent volatility driven by merger speculation and influencer investment. The stock shows bullish technical signals with oversold RSI conditions, while fundamentals reveal persistent challenges with negative net income margins (-28.52%) and declining revenue trends from $1.1B in 2022 to $652M in 2025. The company announced a $285 million merger with Starman Optical and received 11 industry awards for its MISSION 1 series, providing potential catalysts amid ongoing financial struggles.
Investment outlook remains highly speculative with significant execution risks. The merger offers potential upside but faces shareholder litigation over valuation concerns. Analyst consensus shows cautious sentiment with only 21% buy ratings, while cash flow deficits and competitive pressures from smartphone technology create substantial headwinds for sustainable recovery.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
